Compare Stocks → A new way to collect income from stocks (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:KALANASDAQ:KURANASDAQ:NXTCNASDAQ:PRVB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.69-2.4%$0.83$0.50▼$4.67$37.71M0.7645,226 shs34,270 shsKALAKALA BIO$6.47-1.5%$7.41$5.10▼$19.35$18.25M-1.8525,702 shs243 shsKURAKura Oncology$18.68-0.3%$20.73$7.41▼$24.17$1.42B0.851.33 million shs38,098 shsNXTCNextCure$1.53$1.74$0.98▼$2.57$42.69M0.4232,337 shs29,294 shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics-3.19%-0.27%-19.95%+32.96%-82.32%KALAKALA BIO+2.69%-5.66%-18.65%-9.34%-58.73%KURAKura Oncology+2.97%+0.75%-12.48%-4.49%+74.07%NXTCNextCure-4.97%-6.71%-19.47%+30.77%-2.24%PRVBProvention Bio0.00%0.00%0.00%0.00%+2.38%Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new reportMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.8497 of 5 stars3.42.00.04.21.31.71.3KALAKALA BIO3.6259 of 5 stars3.55.00.04.40.00.80.0KURAKura Oncology3.2012 of 5 stars3.41.00.04.71.90.80.0NXTCNextCure3.9331 of 5 stars3.53.00.04.60.01.71.3PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,313.04% UpsideKALAKALA BIO3.00Buy$18.00178.21% UpsideKURAKura Oncology2.88Moderate Buy$28.2851.38% UpsideNXTCNextCure3.00Buy$6.00292.16% UpsidePRVBProvention BioN/AN/AN/AN/ACurrent Analyst RatingsLatest KURA, KALA, CARA, NXTC, and PRVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/6/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/28/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.80N/AN/A$1.05 per share0.66KALAKALA BIO$3.89M4.69N/AN/A$2.79 per share2.32KURAKura OncologyN/AN/AN/AN/A$5.35 per shareN/ANXTCNextCureN/AN/AN/AN/A$4.10 per shareN/APRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)KALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)KURAKura Oncology-$152.63M-$2.08N/AN/AN/AN/A-36.30%-33.12%5/8/2024 (Estimated)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ALatest KURA, KALA, CARA, NXTC, and PRVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/A3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/27/2024Q4 2023KURAKura Oncology-$0.56-$0.55+$0.01-$0.55N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43KALAKALA BIO5.106.336.33KURAKura Oncology0.0212.2612.26NXTCNextCureN/A16.3816.38PRVBProvention Bio0.191.931.92OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%KALAKALA BIO24.61%KURAKura OncologyN/ANXTCNextCure42.65%PRVBProvention Bio37.39%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%KALAKALA BIO13.40%KURAKura Oncology5.50%NXTCNextCure11.90%PRVBProvention Bio13.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.66 million52.36 millionOptionableKALAKALA BIO432.82 million2.44 millionNot OptionableKURAKura Oncology14276.18 million71.99 millionOptionableNXTCNextCure8227.90 million24.58 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableKURA, KALA, CARA, NXTC, and PRVB HeadlinesSourceHeadlineMacrogenics Inc MGNXmorningstar.com - December 29 at 11:00 PMAnd for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetesmedpagetoday.com - November 13 at 5:48 PMTeplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetesnejm.org - October 24 at 9:51 AMFDA sets August decision date for Provention's type 1 diabetes drugpharmaphorum.com - July 23 at 5:52 PMLarry Pine Biography & Moviestribute.ca - June 27 at 3:22 PMSanofi/Provention: innovative diabetes drug is a good fitfinance.yahoo.com - May 1 at 10:47 AMThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%finance.yahoo.com - April 29 at 9:55 AMSanofi completes Provention Bio acquisitionseekingalpha.com - April 28 at 9:22 AMSanofi concludes acquisition of Provention Biomedicaldialogues.in - April 28 at 4:06 AMSanofi completes acquisition of Provention Bio, Inc.pharmiweb.com - April 28 at 4:06 AMEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Declinefinance.yahoo.com - April 27 at 1:01 PMSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.finanznachrichten.de - April 27 at 2:00 AMProvention Bio gains after HSR waiting period for Sanofi deal expiredseekingalpha.com - April 26 at 3:59 PMPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.benzinga.com - April 26 at 10:51 AMSanofi’s $2.9 Billion Provention Bio Deal Draws Investor Lawsuitnews.bloomberglaw.com - April 25 at 11:24 PMPRVB Apr 2023 23.000 putfinance.yahoo.com - April 22 at 10:13 AMSanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Informationmsn.com - April 11 at 3:59 PMProvention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their Estimatesfinance.yahoo.com - April 2 at 10:41 AMGaithersburg’s Novavax locks in consulting deal with outgoing R&D headbizjournals.com - March 27 at 7:11 PM(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?benzinga.com - March 17 at 7:02 PMQ4 2022 MacroGenics Inc Earnings Callfinance.yahoo.com - March 16 at 9:12 AMProvention Bio's Earnings Outlookbenzinga.com - March 15 at 2:10 PMSMBC Nikko Downgrades Provention Bio (PRVB)msn.com - March 14 at 10:52 PMJefferies Downgrades Provention Bio (PRVB)msn.com - March 14 at 10:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Kura OncologyNASDAQ:KURAKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.